Development
ADMA Biologics, Inc.
ADMA
$18.96
-$0.95-4.77%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 67.59% | 79.56% | 89.07% | 93.51% | 90.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.59% | 79.56% | 89.07% | 93.51% | 90.36% |
| Cost of Revenue | 40.70% | 51.26% | 57.24% | 52.99% | 48.95% |
| Gross Profit | 158.17% | 201.36% | 285.80% | 633.83% | 2,905.62% |
| SG&A Expenses | -11.97% | -4.81% | 6.05% | 13.76% | 27.39% |
| Depreciation & Amortization | 1.26% | -0.04% | -0.04% | -0.04% | -0.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.49% | 29.65% | 37.28% | 37.05% | 39.65% |
| Operating Income | 163.84% | 110.41% | 73.15% | 55.68% | 31.63% |
| Income Before Tax | 57.15% | 67.54% | 44.91% | 39.08% | 8.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.15% | 67.54% | 44.91% | 39.08% | 8.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.15% | 67.54% | 44.91% | 39.08% | 8.02% |
| EBIT | 163.84% | 110.41% | 73.15% | 55.68% | 31.63% |
| EBITDA | 203.76% | 132.66% | 86.92% | 65.33% | 38.07% |
| EPS Basic | 62.31% | 70.45% | 53.73% | 52.68% | 37.19% |
| Normalized Basic EPS | 101.92% | 72.17% | 52.95% | 48.56% | 42.95% |
| EPS Diluted | 61.61% | 69.88% | 52.31% | 51.91% | 36.52% |
| Normalized Diluted EPS | 101.71% | 71.97% | 52.95% | 48.56% | 42.95% |
| Average Basic Shares Outstanding | 13.19% | 13.42% | 19.38% | 28.16% | 41.92% |
| Average Diluted Shares Outstanding | 14.26% | 14.53% | 19.38% | 28.16% | 41.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |